DOCSLIB.ORG

Tor Amendment Tagoor Laboratories Private Limited

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ToR Amendment Tagoor Laboratories Private Limited ANNEXURE – I Details of Products as per Granted ToR and Amendment Required Production Capacity S. Ton /Month Therapeutic Product Name No As per Amendment category granted ToR Required 1 Abacavir sulfate 2.0 2.0 Anti HIV 2 Amitriptyline 5.0 10.0 Antidepressant 3 Atrovastatin Calcium 5.0 5.0 Hypercholesterolemia 4 Bupropion 5.0 5.0 Anti depressant 5 carisoprodol 2.0 2.0 Muscle Relaxant 6 Clopidogrelbisulfate 5.0 5.0 Antithrombotic 7 Cyclobenzaprine HCl 5.0 5.0 Muscle relaxant 8 Cyproheptadine HCl 5.0 10.0 Anti allergic 9 Desloratadine 5.0 5.0 Antihistamine 10 Domperidone 20.0 30.0 Anti emetic 11 Domperidone maleate 2.0 2.0 Anti emetic 12 Donepezil HCl 1.0 1.0 Alzheimer’s disease 13 Ebastine 5.0 5.0 Anti allergic 14 Esomeprazole Sodium 3.0 3.0 Anti ulcerative Esomeprazole Magnesium 3.0 3.0 Anti ulcerative 15 trihydrate 16 Fexofenadine Hydrochloride 6.0 15.0 Anti histamine 17 Haloperidol 2.0 2.0 Antipsychotic 18 Itopride Hydrochloride 2.0 2.0 Antispasmodics 19 Itraconazole 10.0 10.0 Antifungal 20 Ketrolac Tromethane 2.0 2.0 Anti Inflammatory 21 Lansoprazole 10.0 10.0 Ant ulcerative 22 Loperamide Hydrochloride 10.0 10.0 Anti diarrhea agent 23 Losartan Potassium 6.0 15.0 Anti Hypertensive 24 Nebivolol HCl 2.0 2.0 Anti Hypertensive 25 Nortriptyline HCl 2.0 2.0 Anti depressant 26 Omeprazole 40.0 40.0 Anti ulcerative 27 Omeprazole Sodium 2.0 2.0 Ant ulcerative Omeprazole Magnesium 2.0 2.0 Ant ulcerative 28 Dihydrate 29 Oxatomide 1.0 1.0 Antihistamine Pantoprazole Sodium Sesqui 10.0 20.0 Ant ulcerative 30 Hydrate 31 Pimozide 2.0 2.0 Antipsychotic 32 Pregabalin 2.0 2.0 Epileptic 33 Quetiapine Hemifumarate 2.0 2.0 Antipsychotic Prepared By Rightsource Industrial Solutions Pvt. Ltd Page 1 ToR Amendment Tagoor Laboratories Private Limited Production Capacity S. Ton /Month Therapeutic Product Name No As per Amendment category granted ToR Required 34 Rabeprazole Sodium 10.0 15.0 Ant ulcerative 35 Rupatadine fumarate 2.0 2.0 Antihistamine 36 Telmisartan 2.0 2.0 Anti Hypertensive 37 Terbinafine hydrochloride 8.0 15.0 Anti fungal 38 Valsartan 2.0 2.0 Anti Hypertensive 39 1-Benzy-4-piperidone 5.0 5.0 Drug Intermediate 40 1-Benzyl-4-chloropiperidine 5.0 5.0 Drug Intermediate 41 1-Benzylpiperidin-4-ol 5.0 5.0 Drug Intermediate 42 1-Methylpiperidin-4-amine 5.0 5.0 Drug Intermediate 43 4-Aminopiperidine 5.0 5.0 Drug Intermediate 44 4-Hydroxy piperidine 5.0 5.0 Drug Intermediate 45 4-Phenylpiperidine 1.0 1.0 Drug Intermediate 46 4-piperidinopiperidine 1.0 1.0 Drug Intermediate N-tert-Butoxycarbonyl-4- 5.0 5.0 Drug Intermediate 47 hydroxy piperidine Total ( Worst Combination of any 12 Products at any 140.0 200.0 given point of time) Note: The above Listed Products, we will manufacture either Finished Product or any Intermediate stage of finished Product as per given quantity by not increasing the production capacity of 200 MT/Month. Prepared By Rightsource Industrial Solutions Pvt. Ltd Page 2 ToR Amendment Tagoor Laboratories Private Limited List of By-Products for ToR Amendment S. Quantity in Product Name By product No. Kg /Day Clopidogrel Bisulphate 1 Omeprazole Ammonium sulphate 3578.08 Domperidone Domperidone 2 Cyclobenzaprinehydrochloride Sodium bromide 656 Itraconazole Cyclobenzaprinehydrochloride Cyproheptadine 3 Magnesium Chloride 290 Hydrochloride Desloratadine Desloratadine 4 Potassium chloride 226 Ebastine Aluminium chloride solution 5 Ebastine 667 (12%) Itraconazole 6 Potassium bromide 84 Telmisartan Pantoprazole sodium 7 sesquihydrate Domperidone Ammonium chloride 2216 8 Desloratadine Ammonium acetate 234 Pantoprazole sodium Acetic acid 506 8 sesquihydrate Ammonium phosphate 773.50 Sodium methyl sulphate 632 Pantoprazole sodium sesquihydrate 9 Domperidone Sodium acetate 1244.45 Rabeprazole sodium Omeprazole 10 Omeprazole Sodium nitrite 545 11 Domperidone Methanol 182 12 Losartan Potassium Trityl alcohol 326 Total 12160.03 Note: The By-Products will be produced according to the combination of required products manufacturing. Prepared By Rightsource Industrial Solutions Pvt. Ltd Page 3 ToR Amendment Tagoor Laboratories Private Limited ANNEXURE – II Details of Water Consumption as per Granted ToR and Amendment Required Water consumptionIn KLD S.No Purpose As per granted ToR Amendment Required 1 Process 40.0 152.5 2 Washings 5.0 6.0 3 Boiler make up 58.5 70.5 4 Cooling towers make up 72.5 119.0 5 Scrubbing system 8.0 18.0 6 Domestic 5.0 6.0 7 Gardening 5.0 5.0 Total 194.00 377.0 Total Water consumption is 377 KLD. 209 KLD of water will be recovered (from Process: 90 KLD & Water Recycled from ZLD System: 119 KLD). Hence, Total fresh water requirement is 377KLD -209 KLD = 168 KLD. Source of water As per Granted ToR: Ground Water Amendment Required: Surface water Allotment from River /Ground Water Details of Waste Water as per Granted ToR and Amendment Required Effluent In KLD S. No Purpose As per granted Amendment ToR Required 1 Process 48.00 98.0 2 Washings 5.00 6.0 3 Boiler Blow down 8.50 10.0 4 Cooling towers Blow down 10.50 15.5 5 Scrubbing system 8.00 15.0 6 Domestic 4.00 5.5 Total 84.00 150.0 Prepared By Rightsource Industrial Solutions Pvt. Ltd Page 4 ToR Amendment Tagoor Laboratories Private Limited ANNEXURE -III Details of Solid & Hazardous Waste Generation and Disposal as per Granted ToR and Amendment Required Quantity S. Details As per Amendment Disposal Method No granted ToR Required Organic waste 1743 2211 Sent to Cement 1 (Process Residue) Kg/Day Kg/Day Industries 167 336 Sent to Cement 2 Spent Carbon Kg/Day Kg/Day Industries Solvent Distillation 1123 2001 Sent to Cement 3 Residue Kg/Day Kg/Day Industries 1216 725 4 Inorganic Waste Sent to TSDF Kg/Day Kg/Day Sent to authorized Spent Mixed 2465 4000 5 recyclers/Cement Solvents Kg/Day Kg/Day Industries 500 .00 500 .00 6 ETP Sludge Sent to TSDF Kg/Day Kg/Day 4387 8684 7 MEE Salts Sent to TSDF Kg/Day Kg/Day Organic Evaporative Liquid 8 0.82KLD 1560 Kg/Day Sent to Cement Industry ( from MEE Stripper) SPCB Authorized 9 Used Oils 500L/Annum 500L/Annum Agencies for Reprocessing/Recycling Detoxified 600 No’s / After Detoxification sent 800 No’s / Month 10 Containers Month to outside agencies. Send back to suppliers Used Lead Acid 11 4 No’s/ Annum 4 No’s/ Annum for buyback of New Batteries Batteries Ash from boiler 11550 Kg/Day Sent to Brick 12 17100 Kg/Day Ash from boiler Manufacturers Prepared By Rightsource Industrial Solutions Pvt. Ltd Page 5 ToR Amendment Tagoor Laboratories Private Limited ANNEXURE - IV UTILITES AS PER GRANTED TOR Boilers: Existing: 6.0 TPH Coal fired/ Agro waste fired Boiler & 2,00,000 kcal/hr Thermo pack Boiler will be continued Proposed: 4.0 TPH Coal fired/ Agro waste fired Boiler is proposed DG Sets: 250 KVA & 500KVA DETAILS OF UTILITIES AS PER AMENDMENT REQUIRED Boilers: Existing: 6.0 TPH Coal fired/ Agro waste fired Boiler will be kept as Standby The existing 2,00,000 kcal/hr. Thermo pack Boiler will be Continued Proposed: 12.0 TPH Coal fired/ Agro waste fired Boiler DG Sets: 1000KVA X 2 no’s STACK EMISSION DETAILS FOR 12 TPH COAL FIRED/ AGRO WASTE FIRED BOILER Particulars Units 12.0 TPH Agro waste / Coal fired Boiler (Proposed) Type of Fuel -- Agro waste /Indian Coal Coal Consumption TPD 48 Ash Content % 35 Sulphur Content % 0.4 No. of Stacks No 1 Height of stack M 32 Diameter of Stack M 0.6 Temperature of Flue oC 220 Gas Velocity of Flue Gas m/s 15 Particulate Matter gm/sec 1.8 Sulphur dioxide gm/sec 2.67 emission Oxides of Nitrogen gm/sec 5.13 emission Pollution control - Cyclone separator followed by equipment suitable pack of Bag filters Note : 6.0 TPH Agro waste /Coal fired boiler (Stand by ) Prepared By Rightsource Industrial Solutions Pvt. Ltd Page 6 ToR Amendment Tagoor Laboratories Private Limited STACK EMISSION DETAILS FOR THERMO PACK BOILER 2,00,000 kcal/hr. Thermo pack Particulars Units Boiler (Existing) Thermo pack Boiler Capacity Kcal/hr. 2,00,000 Type of Fuel -- Agro waste/ Coal Stack Temperature Before oC 250 Air preheater Stack Temperature After Air oC 180 preheater Stack Height m 9.0 Fuel Consumption per Day TPD 0.75 Diameter m 0.30 STACK EMISSION DETAILS FOR DG SETS Emission Emission Emission Stack Flue Gas Stack Flue gas Capacity of SPM in Of SO2 in of NOx In dia. Temp. Height Velocity In KVA 3 3 3 O mg/Nm mg/Nm mg/Nm in m in C in m in m/sec. 1000 KVA 80 50 60 0.2 300 10 16 (Proposed) 1000 KVA 80 50 60 0.2 300 10 16 (Proposed) Prepared By Rightsource Industrial Solutions Pvt. Ltd Page 7 ToR Amendment Tagoor Laboratories Private Limited ANNEXURE -VII Details of Process Emission as per Granted ToR and Amendment Required Quantity In S. Name of the Kg/Day No. Gas As per Amendment Treatment Method granted ToR Required Scrubbed by using 1 Sulphur dioxide 697 1724 C.S.Lye Solution Hydrogen Scrubbed by using 2 330 1183 chloride chilled water media Hydrogen Scrubbed by using C. S. 3 420 311 Bromide Lye solution Dispersed into the 4 Nitrogen 17 45 atmosphere Dispersed into the 5 Carbon dioxide 662 863 atmosphere Diffused by using 6 Hydrogen 16 34 Nitrogen through Flame arrestor Scrubbed by using 7 Ammonia 68 104 chilled water media Dispersed into the 8 Oxygen 136 794 atmosphere Scrubbed by using 9 Chloro Methane 209 242 C.S.Lye Solution Prepared By Rightsource Industrial Solutions Pvt.
Recommended publications
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Relief of Hypersensitivity After Nerve Injury from Systemic Donepezil

    Relief of Hypersensitivity After Nerve Injury from Systemic Donepezil

    Saranya devi Relief of Hypersensitivity after Nerve Injury from ALN Systemic Donepezil Involves Spinal Cholinergic and γ-Aminobutyric Acid Mechanisms Spinal ACh and GABA Mechanisms for Donepezil Analgesia Masafumi Kimura, M.D.,* Ken-ichiro Hayashida, D.V.M., Ph.D.,† James C. Eisenach, M.D.,‡ KIMURA ET AL. Shigeru Saito M.D.,§ Hideaki Obata, M.D.‖ XX ABSTRACT What We Already Know about This Topic • Donepezil increases central nervous system acetylcholine lev- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/118/1/173/259568/0000542-201301000-00030.pdf by guest on 28 September 2021 10.1097/ALN.0b013e318277a81c Background: Evoking spinal release of acetylcholine (ACh) els and is used for treatment of dementia produces antinociception in normal animals and reduces • Increases in spinal acetylcholine levels have been implicated in the relief of neuropathic pain hypersensitivity after nerve injury, and some studies suggest January that ACh-mediated analgesia relies on γ-aminobutyric acid (GABA)-ergic signaling in the spinal cord. In this study, the authors tested the spinal mechanisms underlying the anti- What This Article Tells Us That Is New 118 hypersensitivity effects of donepezil, a central nervous sys- • Donepezil increased spinal acetylcholine levels and γ- tem–penetrating cholinesterase inhibitor, in a rat model of aminobutyric acid levels to reduce nociceptive responses after nerve injury and represents a potential therapeutic pathway to neuropathic pain. reduce pain after nerve injury Methods: Male Sprague-Dawley rats were anesthetized, and L5 spinal nerve ligation was performed unilaterally. With- A antagonist; and CGP 35348 (30 μg), a γ-aminobutyric drawal threshold to a paw pressure test was measured before acid receptor type B antagonist.
  • H1-Antihistamines for Chronic Spontaneous Urticaria: an Abridged Cochrane Systematic Review

    H1-Antihistamines for Chronic Spontaneous Urticaria: an Abridged Cochrane Systematic Review

    H1-antihistamines for chronic spontaneous urticaria: An abridged Cochrane Systematic Review Sharma, Maulina , Bennett, C. , Carter, Ben and Cohen, Stuart N. Author post-print (accepted) deposited by Coventry University’s Repository Original citation & hyperlink: Sharma, Maulina , Bennett, C. , Carter, Ben and Cohen, Stuart N. (2015) H1-antihistamines for chronic spontaneous urticaria: An abridged Cochrane Systematic Review . Journal of the American Academy of Dermatology, volume 73 (4): 710-716 http://dx.doi.org/10.1016/j.jaad.2015.06.048 DOI 10.1016/j.jaad.2015.06.048 ISSN 0190-9622 ESSN 1097-6787 Publisher: Elsevier NOTICE: this is the author’s version of a work that was accepted for publication in Journal of the American Academy of Dermatology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of the American Academy of Dermatology, [VOL 73, ISSUE 4, (2015)] DOI: 10.1016/j.jaad.2015.06.048 © 2015, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS

    Pharmacology on Your Palms CLASSIFICATION of the DRUGS

    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
  • CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology

    CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology

    CT Myelogram Drugs to Avoid Hold for 48 Hours Before and 12 Hours After Your Myelogram UVA Neuroradiology Generic Name (Brand Name) Cidofovir (Vistide) Acetaminophen/butalbital (Allzital; Citalopram (Celexa) Bupap) Clomipramine (Anafranil) Acetaminophen/butalbital/caffeine Clonidine (Catapres; Kapvay) (Fioricet; Butace) Clorazepate (Tranxene-T) Acetaminophen/butalbital/caffeine/ Clozapine (Clozaril; FazaClo; Versacloz) codeine (Fioricet with codeine) Cyclizine (No Brand Name) Acetaminophen/caffeine (Excedrin) Cyclobenzaprine (Flexeril) Acetaminophen/caffeine/dihydrocodeine Desipramine (Norpramine) (Panlor; Trezix) Desvenlafaxine (Pristiq; Khedezla) Acetaminophen/tramadol (Ultracet) Dexmethylphenidate (Focalin) Aliskiren (Tekturna) Dextroamphetamine (Dexedrine; Amitriptyline (Elavil) ProCentra; Zenzedi) Amitriptyline and chlordiazepoxide Dextroamphetamine and amphetamine (Limbril) (Adderall) Amoxapine (Asendin) Diazepam (Valium; Diastat) Aripiprazole (Abilify) Diethylpropion (No Brand Name) Armodafinil (Nuvigil) Dimenhydrinate (Dramamine) Asenapine (Saphris) Donepezil (Aricept) Aspirin/caffeine (BC Powder; Goody Doripenem (Doribax) Powder) Doxapram (Dopram) Atomoxetine (Strattera) Doxepin (Silenor) Baclofen (Gablofen; Lioresal) Droperidol (No Brand Name) Benzphetamine (Didrex; Regimex) Duloxetine (Cymbalta) Benztropine (Cogentin) Entacapone (Comtan) Bismuth Ergotamine and caffeine (Cafergot; subcitrate/metronidazole/tetracycline Migergot) (Pylera) Escitalopram (Lexapro) Bismuth subsalicylate (Pepto-Bismol) Fluoxetine (Prozac; Sarafem)
  • Retrospective Observation of Liver Function Parameters for 101 Patients Using Herbal Drugs for One Month

    Retrospective Observation of Liver Function Parameters for 101 Patients Using Herbal Drugs for One Month

    31 2 (2010 3 ) J Korean Oriental Med 2010;31(2):149-157 Original article 김동민1, 김회권2, 조성연3, 김용석1, 남상수1 1경희대학교 한의과대학 침구학교실, 2가평군 보건소, 3경희대학교 강남경희한방병원 침구과 Retrospective Observation of Liver Function Parameters for 101 Patients Using Herbal Drugs for One Month Dong-Min Kim 1, Hyee-Kwon Kim 2, Seong-Yeun Cho 3, Yong-Suk Kim 1, Sang-Soo Nam 1 1Dept. of Acupuncture & Moxibustion, College of Oriental Medicine, Kyung Hee University 2Gapyeong Public Health Center 3Dept. of Acupuncture & Moxibustion, Kangnam KyungHee Korean Hospital, Kyung Hee University Objective: The purpose of this study was to investigate the level of safety on liver functions when Korean herbal medicine was taken internally. Method: 101 inpatients who took Korean herbal medicine were enrolled and liver function test (aspartic aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, gamma glutamyltranspeptidase, albumin, lactate dehydrogenase) was performed on admission and 1 month later. Results: In 101 patients, alkaline phosphatase and gamma glutamyltranspeptidase decreased significantly compared with the value taken on admission (p<0.05) but aspartic aminotransferase, alanine aminotransferase, total bilirubin, albumin, and lactate dehydrogenase were not significantly changed (p>0.05). In the patients who took Scutellaria baicalensis (n=34), alkaline phosphatase decreased and albumin increased significantly (p<0.05). Among the patients who took Atractylodes macrocephala (n=29), alkaline phosphatase decreased significantly (p<0.05). In the patients who took Glycyrrhiza uralensis or Paeonia lactiflora , liver function parameters were not significantly changed (p>0.05). On admission 11 patients had abnormal liver function and 2 patients had liver injury while 7 patients had abnormal liver function and 2 patients showed liver injury 1 month later.
  • Screening of 300 Drugs in Blood Utilizing Second Generation

    Screening of 300 Drugs in Blood Utilizing Second Generation

    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
  • Overselling Donepezil (ARICEPD and Exploiting Patients V1ith I\Lzheimers Disease: Why Isn't the FDA Stopping These Ads?

    Overselling Donepezil (ARICEPD and Exploiting Patients V1ith I\Lzheimers Disease: Why Isn't the FDA Stopping These Ads?

    PUBLIC CITIZEN HEALTH RESEARCH GROUP SIDNEY M. WOLFE, M.D., EDITOR March 2004 + VOL. 20, N0 . 3 Overselling Donepezil (ARICEPD and Exploiting Patients v1ith i\lzheimers Disease: Why Isn't the FDA Stopping These Ads? n the 1999 Edition of Worst Pills, patients. The ads proclaim that If this conclusion were based on a Best Pills, we urged patients not patients with Alzheimer's disease randomized, placebo-controlled trial I to use donepezil (ARICEPT), who "persistently" use donepezil are (RCT) (the scientific gold standard for made by Pfizer/ Esai, because of a able to stay in the community and medical research) wherein 50 percent combination of adverse effects such avoid going into a nursing home for of the patients got donepezil and the as nausea, diarrhea and vomiting almost two years more than patients other 50 percent of exactly the same along with serious questions about who have only limited treatment or kinds of patients were randomly clinically significant effectiveness. no treatment with the dmg (see assigned to be given a placebo, it We quoted the prestigious Medical advertisement on page 2 for an would be a major public health Letter, an independent evaluation for example). The implication is star­ breakthrough and a cause for cele­ physicians of newly approved dmgs, tling. The families and other friends bration. Unfortunately, it is not based which stated "There is no evidence who are caring for patients with on such a study and is not any cause that use of... donepezil... leads to Alzheimer's disease will have a for celebration. substantial functional improvement substantial amount of extra time to The study cited as the basis for this or prevents the progression of the have their loved ones in the commu­ seemingly remarkable improvement disease." Since then, Pfizer/ Esai has nity before they have to go into a is flawed.
  • Drugs Affectin the Autonomic Nervous System

    Drugs Affectin the Autonomic Nervous System

    Fundamentals of Medical Pharmacology Paterson Public Schools Written by Néstor Collazo, Ph.D. Jonathan Hodges, M.D. Tatiana Mikhaelovsky, M.D. for Health and Related Professions (H.A.R.P.) Academy March 2007 Course Description This fourth year course is designed to give students in the Health and Related Professions (H.A.R.P.) Academy a general and coherent explanation of the science of pharmacology in terms of its basic concepts and principles. Students will learn the properties and interactions between chemical agents (drugs) and living organisms for the rational and safe use of drugs in the control, prevention, and therapy of human disease. The emphasis will be on the fundamental concepts as they apply to the actions of most prototype drugs. In order to exemplify important underlying principles, many of the agents in current use will be singled out for fuller discussion. The course will include the following topics: ¾ The History of Pharmacology ¾ Terminology Used in Pharmacology ¾ Drug Action on Living Organisms ¾ Principles of Pharmacokinetics ¾ Dose-Response Relationships ¾ Time-Response Relationships ¾ Human Variability: Factors that will modify effects of drugs on individuals ¾ Effects of Drugs Attributable to Varying Modes of Administration ¾ Drug Toxicity ¾ Pharmacologic Aspects of Drug Abuse and Drug Dependence Pre-requisites Students must have completed successfully the following courses: Biology, Chemistry, Anatomy and Physiology, Algebra I and II Credits: 5 credits Basic Principles of Drug Action Introduction to Pharmacology a. Basic Mechanisms of Drug Actions b. Dose-response relationships c. Drug absorption d. Biotransformation of Drugs e. Pharmacokinetics f. Factors Affecting Drug Distribution g. Drug Allergy and Pharmacogenetics h.
  • Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction

    Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction

    pharmaceutics Review Potential Herb–Drug Interactions in the Management of Age-Related Cognitive Dysfunction Maria D. Auxtero 1, Susana Chalante 1,Mário R. Abade 1 , Rui Jorge 1,2,3 and Ana I. Fernandes 1,* 1 CiiEM, Interdisciplinary Research Centre Egas Moniz, Instituto Universitário Egas Moniz, Quinta da Granja, Monte de Caparica, 2829-511 Caparica, Portugal; [email protected] (M.D.A.); [email protected] (S.C.); [email protected] (M.R.A.); [email protected] (R.J.) 2 Polytechnic Institute of Santarém, School of Agriculture, Quinta do Galinheiro, 2001-904 Santarém, Portugal 3 CIEQV, Life Quality Research Centre, IPSantarém/IPLeiria, Avenida Dr. Mário Soares, 110, 2040-413 Rio Maior, Portugal * Correspondence: [email protected]; Tel.: +35-12-1294-6823 Abstract: Late-life mild cognitive impairment and dementia represent a significant burden on health- care systems and a unique challenge to medicine due to the currently limited treatment options. Plant phytochemicals have been considered in alternative, or complementary, prevention and treat- ment strategies. Herbals are consumed as such, or as food supplements, whose consumption has recently increased. However, these products are not exempt from adverse effects and pharmaco- logical interactions, presenting a special risk in aged, polymedicated individuals. Understanding pharmacokinetic and pharmacodynamic interactions is warranted to avoid undesirable adverse drug reactions, which may result in unwanted side-effects or therapeutic failure. The present study reviews the potential interactions between selected bioactive compounds (170) used by seniors for cognitive enhancement and representative drugs of 10 pharmacotherapeutic classes commonly prescribed to the middle-aged adults, often multimorbid and polymedicated, to anticipate and prevent risks arising from their co-administration.
  • Donepezil, a Drug for Alzheimer’S Disease, Promotes Oligodendrocyte

    Donepezil, a Drug for Alzheimer’S Disease, Promotes Oligodendrocyte

    www.nature.com/aps ARTICLE Donepezil, a drug for Alzheimer’s disease, promotes oligodendrocyte generation and remyelination Xue Cui1, Yu-e Guo2,3, Jia-hui Fang1, Chang-jie Shi1, Na Suo2,3, Ru Zhang1 and Xin Xie1,2,4 Myelin sheaths play important roles in neuronal functions. In the central nervous system (CNS), the myelin is formed by oligodendrocytes (OLs), which are differentiated from oligodendrocyte precursor cells (OPCs). In CNS demyelinating disorders such as multiple sclerosis (MS), the myelin sheaths are damaged and the remyelination process is hindered. Small molecule drugs that promote OPC to OL differentiation and remyelination may provide a new way to treat these demyelinating diseases. Here we report that donepezil, an acetylcholinesterase inhibitor (AChEI) developed for the treatment of Alzheimer’s disease (AD), significantly promotes OPC to OL differentiation. Interestingly, other AChEIs, including huperzine A, rivastigmine, and tacrine, have no such effect, indicating that donepezil’s effect in promoting OPC differentiation is not dependent on the inhibition of AChE. Donepezil also facilitates the formation of myelin sheaths in OPC–DRG neuron co-culture. More interestingly, donepezil also promotes the repair of the myelin sheaths in vivo and provides significant therapeutic effect in a cuprizone-mediated demyelination animal model. Donepezil is a drug that has been used to treat AD safely for many years; our findings suggest that it might be repurposed to treat CNS demyelinating diseases such as MS by promoting OPC to OL differentiation and remyelination. Keywords: donepezil; aricept; oligodendrocyte; oligodendrocyte progenitor cell; differentiation; myelin sheaths; remyelination; CNS demyelinating disorders; multiple sclerosis Acta Pharmacologica Sinica (2019) 40:1386–1393; https://doi.org/10.1038/s41401-018-0206-4 INTRODUCTION mitochondria function, has been found to accelerate OL matura- Oligodendrocytes (OLs), an important component of neuroglia, tion in culture and increase remyelination in rodents [11, 12].
  • In-Vitro Evaluation of Selected Egyptian Traditional Herbal Medicines for Treatment of Alzheimer Disease

    In-Vitro Evaluation of Selected Egyptian Traditional Herbal Medicines for Treatment of Alzheimer Disease

    Ali et al. BMC Complementary and Alternative Medicine 2013, 13:121 http://www.biomedcentral.com/1472-6882/13/121 RESEARCH ARTICLE Open Access In-vitro evaluation of selected Egyptian traditional herbal medicines for treatment of alzheimer disease Shereen K Ali1, Ahmed R Hamed1,2, Maha M Soltan1,2,UsamaMHegazy3, Esameldin E Elgorashi4, Ibrahim A El-Garf5 and Ahmed A Hussein6* Abstract Background: Egyptians recognized the healing power of herbs and used them in their medicinal formulations. Nowadays, “Attarin” drug shops and the public use mainly the Unani medicinal system for treatment of their health problems including improvement of memory and old age related diseases. Numerous medicinal plants have been described in old literature of Arabic traditional medicine for treatment of Alzheimer’s disease (AD) (or to strengthen memory). Methods: In this study, some of these plants were evaluated against three different preliminary bioassays related to AD to explore the possible way of their bio-interaction. Twenty three selected plants were extracted with methanol and screened in vitro against acetylcholinesterase (AChE) and cycloxygenase-1 (COX-1) enzymes. In addition, anti-oxidant activity using DPPH was determined. Results: Of the tested plant extracts; Adhatoda vasica and Peganum harmala showed inhibitory effect on AChE at IC50 294 μg/ml and 68 μg/ml respectively. Moreover, A. vasica interacted reversibly with the enzyme while P. harmala showed irreversible inhibition. Ferula assafoetida (IC50 3.2 μg/ml), Syzygium aromaticum (34.9 μg/ml) and Zingiber officinalis (33.6 μg/ml) showed activity against COX-1 enzyme. Potent radical scavenging activity was demonstrated by three plant extracts Terminalia chebula (EC50 2.2 μg/ml), T.